Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

PURPOSE: Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-α) is the historic standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab plus IFN-α versus IFN-α m...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rini, Brian I., Halabi, Susan, Rosenberg, Jonathan E., Stadler, Walter M., Vaena, Daniel A., Archer, Laura, Atkins, James N., Picus, Joel, Czaykowski, Piotr, Dutcher, Janice, Small, Eric J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2010
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860433/
https://ncbi.nlm.nih.gov/pubmed/20368558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.5561
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak